• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Delcath Systems Reports First Quarter 2025 Results and Business Highlights

    5/8/25 7:30:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care
    Get the next $DCTH alert in real time by email

    Conference Call Today at 8:30 a.m. Eastern Time

    Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025.

    First Quarter 2025 Financial Results

    • Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024
      • HEPZATO KIT™ revenue of $18.0 million, compared to $2.0 million in the first quarter of 2024
      • CHEMOSAT® revenue of $1.8 million, compared to $1.1 million in the first quarter of 2024
    • Gross margins of 86%, compared to 71% in the first quarter of 2024
    • Net income of $1.1 million, compared to a net loss of $11.1 million in the same quarter of 2024
    • Non-GAAP positive adjusted EBITDA in the first quarter of $7.6 million, compared to a loss of $7.3 million in the first quarter of 2024
    • Cash and investments of $58.9 million as of March 31, 2025
    • Cash provided by operations of $2.2 million in the quarter

    Business Highlights and Updates

    • Activated three new U.S. centers in the first quarter and two more so far in the second quarter of 2025, bringing the current total to 19 active centers, with 10 additional centers accepting referrals
    • Received FDA clearance of an IND application for a phase 2 clinical trial of HEPZATO™ in liver-dominant metastatic breast cancer
    • Announced publication of comparative analysis from randomized portion of FOCUS Study in metastatic uveal melanoma
    • The exercise of 1.62 million Series F warrants resulted in $16.2 million of funding in 2025. The warrants were issued in 2020 as a component of a private placement and had an exercise price of $10.00 per share and expired on May 5, 2025

    "Consistent revenue growth and the continued expansion of active treatment centers represent a strong start to 2025," said Gerard Michel, Chief Executive Officer of Delcath. "We achieved our first quarter of net income and positive operating cash flow, underscoring the accelerating clinical adoption of HEPZATO for patients with metastatic uveal melanoma. Ongoing dialogue with oncologists and interventional radiologists reinforces the importance of whole-liver treatment for patients with liver-dominant disease. These insights continue to shape our development strategy as we pursue additional indications for HEPZATO."

    First Quarter 2025 Results

    Total revenue for the quarter ending March 31, 2025 was $19.8 million compared to $3.1 million for the same period in the prior year. Revenue in the quarter includes sales of $18.0 million of HEPZATO in the U.S. and $1.8 million of CHEMOSAT in Europe.

    Research and development expenses for the quarter ended March 31, 2025, were $5.0 million compared to $3.7 million for the same period in the prior year. The increase is primarily due to costs associated with expanding the clinical team and initiation of the Phase 2 clinical trial evaluating HEPZATO in combination with standard of care for mCRC. In 2024, these costs primarily related to medical affairs and regulatory costs associated with the approved products.

    Selling, general and administrative expenses for the quarter ending March 31, 2025, were $11.3 million compared to $8.8 million for the same period in the prior year. The increase is primarily due to continued commercial expansion activities including marketing-related expenses and additional personnel in the commercial team.

    Net income for the quarter ended March 31, 2025 was $1.1 million compared to net loss of $11.1 million for the same period in the prior year.

    Non-GAAP adjusted EBITDA for the quarter ended March 31, 2025 was $7.6 million compared to adjusted EBITDA loss of $7.3 million for the same period in the prior year. A table reconciling non-GAAP measures is included in this press release for reference.

    As of March 31, 2025, the Company had $58.9 million in cash and investments, and no debt.

    Conference Call Information

    To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call.

    Event Date: Thursday, May 8, 2025

    Time: 8:30 AM Eastern Time

    Participant Numbers:

    Toll Free: 1-877-407-3982

    International: 1-201-493-6780

    Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1713022&tp_key=6de250d858

    A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website https://investors.delcath.com/news-events/events-and-presentations.

    GAAP v. Non-GAAP Measures

    Delcath's reported earnings are prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and represent earnings as reported to the Securities and Exchange Commission. Delcath has provided in this release certain financial information that has not been prepared in accordance with GAAP. Delcath's management believes that the non-GAAP adjusted EBITDA described in this release, which includes adjustments for specific items that are generally not indicative of our core operations, provides additional information that is useful to investors in understanding Delcath's underlying performance, business and performance trends, and helps facilitate period-to-period comparisons and comparisons of its financial measures with other companies in Delcath's industry. However, the non-GAAP financial measures that Delcath uses may differ from measures that other companies may use. Non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation or as substitutes for results prepared in accordance with GAAP.

    About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT

    Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure.

    In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information, including BOXED WARNING for the HEPZATO KIT.

    In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

    Safe Harbor / Forward-Looking Statements

    The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This press release contains forward-looking statements, which are subject to certain risks and uncertainties, that can cause actual results to differ materially from those described. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the Company's commercialization plans and its ability to successfully commercialize the HEPZATO KIT; contributions to adjusted EBITDA; the Company's successful management of the HEPZATO KIT supply chain, including securing adequate supply of critical components necessary to manufacture and assemble the HEPZATO KIT; successful FDA inspections of the facilities of the Company and those of its third-party suppliers/manufacturers; the Company's successful implementation and management of the HEPZATO KIT Risk Evaluation and Mitigation Strategy; the potential benefits of the HEPZATO KIT as a treatment for patients with primary and metastatic disease in the liver; the Company's ability to obtain reimbursement for the HEPZATO KIT; and the Company's ability to successfully enter into any necessary purchase and sale agreements with users of the HEPZATO KIT. For additional information about these factors, and others that may impact the Company, please see the Company's filings with the Securities and Exchange Commission, including those on Forms 10-K, 10-Q, and 8-K. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, you should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

    DELCATH SYSTEMS, INC.

    Condensed Consolidated Balance Sheets

    (Unaudited)

    (in thousands, except share and per share data)

     

    March 31,

    2025

     

    December 31,

    2024

    Assets

     

     

     

    Current assets

     

     

     

    Cash and cash equivalents

    $

    12,776

     

     

    $

    32,412

     

    Short-term investments

     

    46,120

     

     

     

    20,821

     

    Accounts receivable

     

    13,942

     

     

     

    10,890

     

    Inventories

     

    7,132

     

     

     

    6,933

     

    Prepaid expenses and other current assets

     

    4,379

     

     

     

    2,704

     

    Total current assets

     

    84,349

     

     

     

    73,760

     

    Property, plant and equipment, net

     

    1,954

     

     

     

    1,790

     

    Right-of-use assets

     

    1,016

     

     

     

    1,039

     

    Total assets

    $

    87,319

     

     

    $

    76,589

     

    Liabilities and Stockholders' Equity

     

     

     

    Current liabilities

     

     

     

    Accounts payable

    $

    1,619

     

     

    $

    961

     

    Accrued expenses

     

    3,558

     

     

     

    5,078

     

    Lease liabilities, current

     

    110

     

     

     

    105

     

    Total current liabilities

     

    5,287

     

     

     

    6,144

     

    Lease Liabilities, non-current

     

    906

     

     

     

    933

     

    Other liabilities, non-current

     

    896

     

     

     

    766

     

    Total liabilities

    $

    7,089

     

     

    $

    7,843

     

    Commitments and contingencies

     

     

     

    Stockholders' equity

     

     

     

    Preferred stock, $0.01 par value; 10,000,000 shares authorized; 14,192 and 14,192 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively

     

    —

     

     

     

    —

     

    Common stock, $0.01 par value; 80,000,000 shares authorized; 33,436,612 shares and 33,061,002 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively

     

    334

     

     

     

    331

     

    Additional paid-in capital

     

    609,994

     

     

     

    599,881

     

    Accumulated deficit

     

    (530,479

    )

     

     

    (531,548

    )

    Accumulated other comprehensive income

     

    381

     

     

     

    82

     

    Total stockholders' equity

     

    80,230

     

     

     

    68,746

     

    Total liabilities and stockholders' equity

    $

    87,319

     

     

    $

    76,589

     

    DELCATH SYSTEMS, INC.

    Condensed Consolidated Statements of Operations and Comprehensive Loss

    (Unaudited)

    (in thousands, except share and per share data)

     

    Three months ended March 31,

     

     

    2025

     

     

     

    2024

     

    Product revenue

    $

    19,784

     

     

    $

    3,139

     

    Cost of goods sold

     

    (2,845

    )

     

     

    (903

    )

    Gross profit

     

    16,939

     

     

     

    2,236

     

    Operating expenses:

     

     

     

    Research and development expenses

     

    5,007

     

     

     

    3,700

     

    Selling, general and administrative expenses

     

    11,290

     

     

     

    8,814

     

    Total operating expenses

     

    16,297

     

     

     

    12,514

     

    Operating gain (loss)

     

    642

     

     

     

    (10,278

    )

    Change in fair value of warrant liability

     

    —

     

     

     

    (612

    )

    Interest income (expense), net

     

    618

     

     

     

    (199

    )

    Other income (expense)

     

    4

     

     

     

    (22

    )

    Income (loss) before income taxes

     

    1,264

     

     

     

    (11,111

    )

    Income tax expense

     

    195

     

     

     

    —

     

    Net income (loss)

     

    1,069

     

     

     

    (11,111

    )

    Other comprehensive income (loss):

     

     

     

    Unrealized gain on investments adjustments

     

    239

     

     

     

    8

     

    Foreign currency translation adjustments

     

    60

     

     

     

    14

     

    Total comprehensive income (loss)

    $

    1,368

     

     

    $

    (11,089

    )

    Common share data:

     

     

     

    Basic income (loss) per common share

    $

    0.03

     

     

    $

    (0.45

    )

    Weighted average number of basic shares outstanding

     

    34,642,641

     

     

     

    24,887,180

     

    Diluted income (loss) per common share

    $

    0.03

     

     

    $

    (0.45

    )

    Weighted average number of dilutive shares outstanding

     

    39,511,120

     

     

     

    24,887,180

     

    DELCATH SYSTEMS, INC.

    Reconciliation of Reported Net Income (Loss) (GAAP) to Adjusted EBITDA (NON-GAAP Measure)

    (Unaudited)

    (in thousands)

    Three months ended December 31,

     

     

    2025

     

     

     

    2024

     

    Net income (loss)

    $

    1,069

     

     

    $

    (11,111

    )

    Stock-based compensation expense

     

    6,863

     

     

     

    2,945

     

    Depreciation

     

    43

     

     

     

    29

     

    Net interest (income) expense

     

    (618

    )

     

     

    199

     

    Fair value warrant adjustment

     

    —

     

     

     

    612

     

    Income tax expense

     

    195

     

     

     

    —

     

    Adjusted EBITDA (Non-GAAP)

    $

    7,552

     

     

    $

    (7,326

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250508705446/en/

    Investor Relations Contact:

    ICR Westwicke

    [email protected]

    Get the next $DCTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DCTH

    DatePrice TargetRatingAnalyst
    6/28/2024$18.00Buy
    Craig Hallum
    5/14/2024$25.00Overweight
    Stephens
    7/26/2022$17.00Buy
    Canaccord Genuity
    12/10/2021$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $DCTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Beta Bionics Announces Board Appointment of Gerard Michel

      IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a

      3/27/25 4:45:06 PM ET
      $BBNX
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

      Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa

      5/28/24 9:30:00 AM ET
      $ACHV
      $ALGS
      $DCTH
      $PNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medical/Dental Instruments
    • Delcath Systems Appoints Martha S. Rook as Chief Operating Officer

      NEW YORK, March 18, 2024 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Martha S. Rook as its new Chief Operating Officer (COO). Martha S. Rook, Ph.D., is an experienced industry leader who brings more than 25 years of academic and industry experience in molecular biology, diagnostics development, biologics process development and biologics manufacturing. She joins Delcath from insitro where she

      3/18/24 5:20:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

      SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/15/24 10:33:51 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

      SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/14/24 9:46:56 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Delcath Systems Inc.

      SC 13G/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

      11/14/24 7:02:01 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Financials

    Live finance-specific insights

    See more
    • Delcath Systems Reports First Quarter 2025 Results and Business Highlights

      Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024 HEPZATO KIT™ revenue of $18.0 million, compared to $2.0 million in the first quarter of 2024 CHEMOSAT® revenue of $1.8 million, compared to $1.1 million in the first quarter of 2024 Gross margins of 86%, compared to 71% in the first quarter of 2

      5/8/25 7:30:00 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems to Host First Quarter 2025 Earnings Call

      Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 8, 2025, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, May 8, 2025 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1713022&tp_key=6de250d858 A replay of the webinar will be available shortly a

      4/24/25 4:01:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

      Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2024. Fourth Quarter and Full Year 2024 Financial Results Total fourth quarter and full year revenue of $15.1 million and $37.2 million, respectively HEPZATO KIT™ fourth quarter and full year revenue of $13.7 million and $32.3 million, respectively CHEMOSAT® fourth quarter and full year revenue of $1.4 million and $4.9 million, respectively Gross mar

      3/6/25 8:00:00 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $DCTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $DCTH
    SEC Filings

    See more
    • Delcath Systems Reports First Quarter 2025 Results and Business Highlights

      Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Total revenue of $19.8 million, compared with $3.1 million in the first quarter of 2024 HEPZATO KIT™ revenue of $18.0 million, compared to $2.0 million in the first quarter of 2024 CHEMOSAT® revenue of $1.8 million, compared to $1.1 million in the first quarter of 2024 Gross margins of 86%, compared to 71% in the first quarter of 2

      5/8/25 7:30:00 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

      Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the Company's Investigational New Drug (IND) application for a Phase 2 clinical trial evaluating HEPZATO™ in combination with standard of care (SOC) for liver-dominant metastatic breast cancer (mBC). With the FDA's review complete, Delcath is now cleared to initiate patient enrollment in the U.S. The Phase 2 trial will evaluate the safety and efficacy of HEPZATO in combination with SOC versus SOC alone in patients with liver-dominant HER2-negative mBC foll

      4/28/25 8:30:00 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems to Host First Quarter 2025 Earnings Call

      Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 8, 2025, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, May 8, 2025 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1713022&tp_key=6de250d858 A replay of the webinar will be available shortly a

      4/24/25 4:01:00 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

      10/2/24 4:43:10 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling

      5/23/24 10:32:08 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

      Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-4) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 01/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

      1/23/24 4:36:46 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Delcath Systems Inc.

      10-Q - DELCATH SYSTEMS, INC. (0000872912) (Filer)

      5/8/25 9:25:44 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Delcath Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)

      5/8/25 7:42:05 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Delcath Systems Inc.

      DEFA14A - DELCATH SYSTEMS, INC. (0000872912) (Filer)

      4/1/25 8:58:05 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Delcath with a new price target

      Craig Hallum initiated coverage of Delcath with a rating of Buy and set a new price target of $18.00

      6/28/24 8:18:39 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Stephens initiated coverage on Delcath with a new price target

      Stephens initiated coverage of Delcath with a rating of Overweight and set a new price target of $25.00

      5/14/24 7:58:22 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Canaccord Genuity resumed coverage on Delcath with a new price target

      Canaccord Genuity resumed coverage of Delcath with a rating of Buy and set a new price target of $17.00

      7/26/22 9:10:21 AM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Aharon Gil exercised 400,000 in-the-money shares at a strike of $10.00 (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      5/9/25 1:00:03 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Director Salamon Steven A J exercised 400,000 in-the-money shares at a strike of $10.00 (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      5/9/25 12:36:53 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Director Rosalind Advisors, Inc. exercised 400,000 in-the-money shares at a strike of $10.00 (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      5/9/25 12:15:14 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care

    $DCTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Aharon Gil bought $100,001 worth of shares (26,882 units at $3.72), increasing direct ownership by 3% to 1,069,710 units (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      3/20/24 8:00:14 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Salamon Steven A J bought $100,001 worth of shares (26,882 units at $3.72), increasing direct ownership by 2% to 1,121,025 units (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      3/20/24 7:44:56 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care
    • Vukovic Vojo bought $120,000 worth of shares (40,000 units at $3.00), increasing direct ownership by 67% to 100,000 units (SEC Form 4)

      4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

      12/14/23 4:20:16 PM ET
      $DCTH
      Medical/Dental Instruments
      Health Care